• OPEN AN ACCOUNT
Indian Indices
Nifty
24,973.10 104.50
(0.42%)
Sensex
81,425.15 323.83
( 0.40%)
Bank Nifty
54,536.00 319.90
( 0.59%)
Nifty IT
36,183.80 927.90
( 2.63%)
Global Indices
Nasdaq
45,729.90 193.94
(0.43%)
Dow Jones
6,533.40 17.25
(0.26%)
Hang Seng
43,788.68 329.39
(0.76%)
Nikkei 225
9,242.53 21.09
(0.23%)
Forex
USD-INR
88.02 -0.16
(-0.18%)
EUR-INR
103.30 -0.01
(-0.01%)
GBP-INR
119.05 -0.02
(-0.01%)
JPY-INR
0.60 0.00
(-0.34%)

EQUITY - MARKET SCREENER

Medicamen Organics Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
92885
INE0PE401018
24.7648718
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MEDIORG
11.79
38.61
EPS(TTM)
Face Value()
Div & Yield %
2.8
10
0
 

hcp plastene bulkpack ltd
Marksans Pharma rises as UK subsidiary gets approval for Metformin Prolonged release tablets
Aug 18,2025
The approval was granted by the UK regulatory authorities, allowing Relonchem to market the widely used anti-diabetic medication in three dosage strengths. Metformin is commonly prescribed for the treatment of type 2 diabetes and is considered a frontline therapy for managing blood glucose levels.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25.